Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities.
Long term clinical benefit of lenalidomide (Revlimid) treatment in patients with myelodysplastic syndrome without del 5q cytogenetic abnormalities. Raza, A., Reeves, J. E., Feldman, E. J., Deeg, H., Dreisbach, L., Schiffer, C. A., Shammo, J. M., Klimek, V. M., Greenberg, P. L., Bennett, J. M., DeWald, G. W., Zeldis, J. B., Wride, K., Schmidt, M., Knight, R. D., List, A. F. AMER SOC HEMATOLOGY. 2006: 78AView details for Web of Science ID 000242440000251